Several studies have demonstrated the feasibility of monitoring EGFR mutations in plasma to evaluate the treatment response to TKIs and predict clinical outcome of NSCLC patients [24, 30–32]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.